文献速递技术与安全胸部泌尿生殖CT

基于CT的影像组学特征与晚期实体瘤免疫检查点抑制剂治疗反应相关

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
PubMed 文献 · Radiology · 2021-01-26

本研究回顾性开发并验证了治疗前CT影像组学特征,用于预测晚期实体瘤患者对免疫检查点抑制剂的反应。影像组学特征与临床反应相关(AUC 0.70),并在膀胱癌和肺癌队列中验证(AUC均为0.67),联合临床变量后AUC提升至0.74。

要点

  • 治疗前CT影像组学特征与免疫检查点抑制剂反应相关,开发队列AUC为0.70。
  • 膀胱癌和肺癌验证队列AUC均为0.67,提示特征有一定泛化性。
  • 联合基线白蛋白和淋巴细胞计数可提升预测性能至AUC 0.74。

核心结论

  • 治疗前基于CT的影像组学特征与免疫检查点抑制剂治疗反应相关,可能反映肿瘤免疫表型。

研究设计与样本

  • 回顾性研究,影像组学特征在85例晚期实体瘤患者(队列1,包括乳腺癌、宫颈癌、胃肠道肿瘤)中开发,患者于2012年8月至2018年5月接受抗PD-1或PD-L1单药治疗。
  • 特征在46例膀胱癌患者(队列2)和47例肺癌患者(队列3)中测试;另在20例患者(队列4)中进行生物学验证(细胞毒性细胞RNA表达谱)。
  • 影像组学变量从治疗前CT上所有转移灶勾画中提取,采用弹性网模型筛选,并结合临床变量建立回归模型,以治疗反应为终点。

关键影像表现/征象

  • 影像组学特征从所有转移灶中提取,具体影像征象原文未详述。

诊断标准与关键数值

  • 影像组学特征预测临床反应的AUC为0.70(95% CI: 0.64, 0.77;P < .001)。
  • 队列2(膀胱癌)AUC为0.67(95% CI: 0.58, 0.76),队列3(肺癌)AUC为0.67(95% CI: 0.56, 0.77;P < .001)。
  • 影像组学联合临床特征(包括基线白蛋白水平和淋巴细胞计数)的AUC为0.74(95% CI: 0.63, 0.84;P < .001),赤池信息准则分别为107.00和109.90。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature to predict response to immune checkpoint inhibitors in advanced solid tumors. Materials and Methods In this retrospective study, a radiomics signature was developed in patients with advanced solid tumors (including breast, cervix, gastrointestinal) treated with anti-programmed cell death-1 or programmed cell death ligand-1 monotherapy from August 2012 to May 2018 (cohort 1). This was tested in patients with bladder and lung cancer (cohorts 2 and 3). Radiomics variables were extracted from all metastases delineated at pretreatment CT and selected by using an elastic-net model. A regression model combined radiomics and clinical variables with response as the end point. Biologic validation of the radiomics score with RNA profiling of cytotoxic cells (cohort 4) was assessed with Mann-Whitney analysis. Results The radiomics signature was developed in 85 patients (cohort 1: mean age, 58 years ± 13 [standard deviation]; 43 men) and tested on 46 patients (cohort 2: mean age, 70 years ± 12; 37 men) and 47 patients (cohort 3: mean age, 64 years ± 11; 40 men). Biologic validation was performed in a further cohort of 20 patients (cohort 4: mean age, 60 years ± 13; 14 men). The radiomics signature was associated with clinical response to immune checkpoint inhibitors (area under the curve [AUC], 0.70; 95% CI: 0.64, 0.77; P < .001). In cohorts 2 and 3, the AUC was 0.67 (95% CI: 0.58, 0.76) and 0.67 (95% CI: 0.56, 0.77; P < .001), respectively. A radiomics-clinical signature (including baseline albumin level and lymphocyte count) improved on radiomics-only performance (AUC, 0.74 [95% CI: 0.63, 0.84; P < .001]; Akaike information criterion, 107.00 and 109.90, respectively). Conclusion A pretreatment CT-based radiomics signature is associated with response to immune checkpoint inhibitors, likely reflecting the tumor immunophenotype. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Summers in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ligero M, Garcia-Ruiz A, Viaplana C, et al. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021. PMID: 33497314. doi:10.1148/radiol.2021200928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。